Paper36450828
First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens.
Moiseev I and 7 others. Bone Marrow Transplant, 2023. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens. Papers, record 36450828. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36450828
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bronchiolitis Obliterans Syndrome | Major topic |
| Graft vs Host Disease | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Humans | |
| Cyclophosphamide | |
| Bone Marrow Transplantation | |
| Calcineurin Inhibitors | |
| Adrenal Cortex Hormones | |
| Acute Disease |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 17-75-20145 | Russian Science Foundation (RSF) | PubMed |
Source PubMed
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23892326 | Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. | Bone Marrow Transplant | 2014 | https://conductscience.org/library/papers/23892326 | PubMed |
| 2 | 34049582 | Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. | J Hematol Oncol | 2021 | https://conductscience.org/library/papers/34049582 | PubMed |
| 3 | 7004534 | Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. | Blood | 1981 | https://conductscience.org/library/papers/7004534 | PubMed |
| 4 | 3042041 | Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. | Blood | 1988 | https://conductscience.org/library/papers/3042041 | PubMed |
| 5 | 7581076 | 1994 Consensus Conference on Acute GVHD Grading. | Bone Marrow Transplant | 1995 | https://conductscience.org/library/papers/7581076 | PubMed |
| 6 | 34087452 | Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. | Transplant Cell Ther | 2021 | https://conductscience.org/library/papers/34087452 | PubMed |
| 7 | 24225944 | Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. | Sci Transl Med | 2013 | https://conductscience.org/library/papers/24225944 | PubMed |
| 8 | 25796139 | Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. | Biol Blood Marrow Transplant | 2015 | https://conductscience.org/library/papers/25796139 | PubMed |
| 9 | 25113844 | Transcriptome profiling of CTLs regulated by rapamycin using RNA-Seq. | Immunogenetics | 2014 | https://conductscience.org/library/papers/25113844 | PubMed |
| 10 | 18489989 | HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. | Biol Blood Marrow Transplant | 2008 | https://conductscience.org/library/papers/18489989 | PubMed |
| 11 | 30674564 | Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. | J Exp Med | 2019 | https://conductscience.org/library/papers/30674564 | PubMed |
| 12 | 21383686 | Prognostic value of response after upfront therapy for acute GVHD. | Bone Marrow Transplant | 2012 | https://conductscience.org/library/papers/21383686 | PubMed |
| 13 | 7023233 | Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. | Am J Hematol | 1981 | https://conductscience.org/library/papers/7023233 | PubMed |
| 14 | 20124511 | High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. | Blood | 2010 | https://conductscience.org/library/papers/20124511 | PubMed |
| 15 | 34855460 | Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/34855460 | PubMed |
| 16 | 34535015 | Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. | Blood Adv | 2021 | https://conductscience.org/library/papers/34535015 | PubMed |
| 17 | 16338616 | National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. | Biol Blood Marrow Transplant | 2005 | https://conductscience.org/library/papers/16338616 | PubMed |
| 18 | 31700138 | Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. | Bone Marrow Transplant | 2020 | https://conductscience.org/library/papers/31700138 | PubMed |
| 19 | 33257777 | Incorporation of posttransplant cyclophosphamide as part of standard immunoprophylaxis for all allogeneic transplants: a retrospective, single institution study. | Bone Marrow Transplant | 2021 | https://conductscience.org/library/papers/33257777 | PubMed |
| 20 | 26611557 | Infection Risk and Safety of Corticosteroid Use. | Rheum Dis Clin North Am | 2016 | https://conductscience.org/library/papers/26611557 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 39207560 | Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease. | Ann Hematol | 2025 | https://conductscience.org/library/papers/39207560 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| APP | 351 | PubTator's text mining | https://conductscience.org/library/genes/351 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36450828
GET https://conductscience.org/api/papers/v1/36450828/references?page=2